Frozen Meat Market Size, Share & Trends Analysis Report By Product (Beef, Chicken, Pork), By Distribution Channel (Convenience Stores, Supermarkets & Hypermarkets, Online), By Region, And Segment Forecasts, 2025 - 2030

Frozen Meat Market Size, Share & Trends Analysis Report By Product (Beef, Chicken, Pork), By Distribution Channel (Convenience Stores, Supermarkets & Hypermarkets, Online), By Region, And Segment Forecasts, 2025 - 2030


Frozen Meat Market Report Highlights

The global frozen meat market size is anticipated to reach USD 115.76 billion by 2030, expanding at a CAGR of 3.1% over the forecast period, according to a new report by Grand View Research, Inc. The market is driven by increase in adoption of ready to eat food and change in lifestyle and food preference, where seasonality remains the major factor.

The market is gaining popularity among consumers due to the readily consumable aspect of the product, which saves time for the busy and young professionals. This is expected to provide potential growth opportunities for the global market. Over the past few years, stable economic growth associated with developing mining industry has resulted in increasing number of employment opportunities, thereby improving the consumers’ average income.

Rapid urbanization as a result of growing population and need to cater to the increasing demand for non-vegetarian consumers are some of the factors expected to boost market growth in the coming years. Recent spread of diseases in pork and poultry has resulted in the gradual shift of the consumers towards beef and other meat products.

The frozen beef product segment held the largest market share in 2024. For instance, China imported USD 3 billion worth of frozen beef in 2017, which is 13.8% of the total frozen beef. U.S. was the second largest importer of frozen beef holding a share of 10.3%, followed by Vietnam, Hong Kong, and South Korea. Vietnam, China, and Indonesia are the fastest growing importers of frozen beef while countries like Japan, Russia, and Israel have declined in the purchase of frozen beef imports.

The supermarket and hypermarket segment is anticipated to expand at the fastest CAGR over the forecast period. The online segment held the largest market share in 2018 owing to technological advancements across the world. The online channel is expected to witness increased adoption among consumers over the coming years. Time-pressed younger population, especially in the metros, is expected to be a key consumer set for active players such as Grofers and Big Basket, which have been the front runners in online grocery retailing at large.

Asia Pacific held the largest market share in 2018 and is anticipated to expand at the highest CAGR of 5.2% over the forecast period. The growth is attributed to high import and consumption of meat in this region, along with penetration of e-commerce, increase in the number of food joints, and seasonality. Increasing popularity of healthy products among Chinese consumers is projected to increase demand for frozen meat. Young consumer, especially aged 20 year to 35 year eat healthy meat product once a week. Dumpling is the most consumed product, especially in urban areas. Consumers in the above-mentioned age group also buy frozen meat from online retailers. For instance, 64% of the population in China was in the 16-59 years age group in 2017, which presents growth prospect for the online channel.

Leading players in the market include Kerry Group Plc.; Marfrig Group.; BRF S.A.; Associated British Foods Plc.; Tyson Foods; Pilgrim’s Pride Corporation, Inc.; Verde Farms, LLC; and Arcadian Organic & Natural Meat Co.

Frozen Meat Market Report Highlights
  • Frozen beef is expected to expand at the highest CAGR over the forecast period. The segment held the largest market share of 33.0% in 2024 and is expected to maintain its lead in the coming years
  • Based on the distribution channel, the supermarket and hypermarket segment is anticipated to expand at the fastest CAGR over the forecast period
  • APAC held the largest market share in 2024owing to developing countries like China and Japan. The region is expected to register the highest CAGR of 5.2% over the forecast period
  • Various manufacturers are focusing on technological innovation in order to gain maximum market share.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.1.1. Approach 1: Commodity flow approach
1.7.2. Volume price analysis (Model 2)
1.7.2.1. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Biopharmaceuticals Contract Manufacturing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Rise in investment by CMOs for capacity expansion
3.2.1.2. Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
3.2.1.3. Notable growth of biologics approvals
3.2.1.4. Robust biopharmaceuticals pipeline
3.2.1.5. Cost and time-saving benefits offered by contract services
3.2.2. Market Restraints Analysis
3.2.2.1. Limited outsourcing amongst well-established biopharmaceutical manufacturer
3.2.2.2. Managing Relationships
3.3. Product Pipeline Analysis
3.4. Pricing Model Analysis
3.5. Market Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
Chapter 4. Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Source Movement Analysis
4.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Source, 2018-2030 (USD Million)
4.4. Mammalian
4.4.1. Mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Non-mammalian
4.5.1. Non-mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Service Movement Analysis
5.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Service, 2018-2030 (USD Million)
5.4. Process Development
5.4.1. Process Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.2. Downstream Processing
5.4.2.1. Downstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.3. Upstream Processing
5.4.3.1. Upstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Fill & Finish Operations
5.5.1. Fill & Finish Operations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Analytical & QC Studies
5.6.1. Analytical & QC Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Packaging & Labelling
5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Biopharmaceuticals Contract Manufacturing Market: Drug Type Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Drug Type Movement Analysis
6.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Drug Type, 2018-2030 (USD Million)
6.4. Biologics
6.4.1. Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Monoclonal Antibodies
6.4.2.1. Monoclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Recombinant proteins
6.4.3.1. Recombinant Proteins Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. Vaccines
6.4.4.1. Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5. Antisense, RNAi, & Molecular Therapy
6.4.5.1. Antisense, RNAi, & Molecular Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6. Others
6.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Biosimilar
6.5.1. Biosimilar Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Biopharmaceuticals Contract Manufacturing Market: Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Type Movement Analysis
7.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Type, 2018-2030 (USD Million)
7.4. Drug Substance
7.4.1. Drug Substance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Finished Drug Product
7.5.1. Finished Drug Product Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Scale of Operation Movement Analysis
8.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Scale of Operation, 2018-2030 (USD Million)
8.4. Clinical
8.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Commercial
8.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis
9.1. Segment Dashboard
9.2. Therapeutic Area Movement Analysis
9.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Therapeutic Area, 2018-2030 (USD Million)
9.4. Oncology
9.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. Autoimmune Diseases
9.5.1. Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Infectious Diseases
9.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7. Cardiovascular Diseases
9.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.8. Metabolic Diseases
9.8.1. Metabolic Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.9. Neurology
9.9.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.10. Others
9.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 10. Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis
10.1. Regional market share analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. North America
10.3.1. North America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.3.2. U.S.
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Landscape
10.3.2.4. U.S. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.3.3. Canada
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Landscape
10.3.3.4. Canada Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.3.4. Mexico
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Landscape
10.3.4.4. Mexico Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4. Europe
10.4.1. Europe Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.2. U.K.
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Landscape
10.4.2.4. U.K. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.3. Germany
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Landscape
10.4.3.4. Germany Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.4. France
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Landscape
10.4.4.4. France Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.5. Italy
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Regulatory Landscape
10.4.5.4. Italy Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.6. Spain
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Regulatory Landscape
10.4.6.4. Spain Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.7. Denmark
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Regulatory Landscape
10.4.7.4. Denmark Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.8. Sweden
10.4.8.1. Key Country Dynamics
10.4.8.2. Competitive Scenario
10.4.8.3. Regulatory Landscape
10.4.8.4. Sweden Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.9. Norway
10.4.9.1. Key Country Dynamics
10.4.9.2. Competitive Scenario
10.4.9.3. Regulatory Landscape
10.4.9.4. Norway Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5. Asia Pacific
10.5.1. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.2. China
10.5.2.1. Key Country Dynamics
10.5.2.2. Competitive Scenario
10.5.2.3. Regulatory Landscape
10.5.2.4. China Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.3. Japan
10.5.3.1. Key Country Dynamics
10.5.3.2. Competitive Scenario
10.5.3.3. Regulatory Landscape
10.5.3.4. Japan Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.4. India
10.5.4.1. Key Country Dynamics
10.5.4.2. Competitive Scenario
10.5.4.3. Regulatory Landscape
10.5.4.4. India Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.5. South Korea
10.5.5.1. Key Country Dynamics
10.5.5.2. Competitive Scenario
10.5.5.3. Regulatory Landscape
10.5.5.4. South Korea Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.6. Australia
10.5.6.1. Key Country Dynamics
10.5.6.2. Competitive Scenario
10.5.6.3. Regulatory Landscape
10.5.6.4. Australia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.7. Thailand
10.5.7.1. Key Country Dynamics
10.5.7.2. Competitive Scenario
10.5.7.3. Regulatory Landscape
10.5.7.4. Thailand Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6. Latin America
10.6.1. Latin America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.2. Brazil
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Regulatory Landscape
10.6.2.4. Brazil Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.3. Argentina
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Regulatory Landscape
10.6.3.4. Argentina Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7. Middle East and Africa
10.7.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.2. Saudi Arabia
10.7.2.1. Key Country Dynamics
10.7.2.2. Competitive Scenario
10.7.2.3. Regulatory Landscape
10.7.2.4. Saudi Arabia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.3. UAE
10.7.3.1. Key Country Dynamics
10.7.3.2. Competitive Scenario
10.7.3.3. Regulatory Landscape
10.7.3.4. UAE Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.4. South Africa
10.7.4.1. Key Country Dynamics
10.7.4.2. Competitive Scenario
10.7.4.3. Regulatory Landscape
10.7.4.4. South Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.5. Kuwait
10.7.5.1. Key Country Dynamics
10.7.5.2. Competitive Scenario
10.7.5.3. Regulatory Landscape
10.7.5.4. Kuwait Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 11. Competitive Landscape
11.1. Company Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
11.3. Company Profiles
11.3.1. Boehringer Ingelheim GmbH
11.3.1.1. Participant’s Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Lonza
11.3.2.1. Participant’s Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. Inno Biologics Sdn Bhd
11.3.3.1. Participant’s Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. Rentschler Biotechnologies GmbH
11.3.4.1. Participant’s Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. JRS PHARMA
11.3.5.1. Participant’s Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. AGC Biologics
11.3.6.1. Participant’s Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. ProBioGen
11.3.7.1. Participant’s Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
11.3.8.1. Participant’s Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Toyobo Co. Ltd.
11.3.9.1. Participant’s Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. Samsung Biologics
11.3.10.1.1. Participant’s Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. Thermo Fisher Scientific, Inc.
11.3.11.1. Participant’s Overview
11.3.11.2. Financial Performance
11.3.11.3. Service Benchmarking
11.3.11.4. Strategic Initiatives
11.3.12. Binex Co., Ltd.
11.3.12.1. Participant’s Overview
11.3.12.2. Financial Performance
11.3.12.3. Service Benchmarking
11.3.12.4. Strategic Initiatives
11.3.13. WuXi Biologics
11.3.13.1. Participant’s Overview
11.3.13.2. Financial Performance
11.3.13.3. Service Benchmarking
11.3.13.4. Strategic Initiatives
11.3.14. AbbVie, Inc.
11.3.14.1. Participant’s Overview
11.3.14.2. Financial Performance
11.3.14.3. Service Benchmarking
11.3.14.4. Strategic Initiatives
11.3.15. ADMA Biologics, Inc.
11.3.15.1. Participant’s Overview
11.3.15.2. Financial Performance
11.3.15.3. Service Benchmarking
11.3.15.4. Strategic Initiatives
11.3.16. Catalent, Inc
11.3.16.1. Participant’s Overview
11.3.16.2. Financial Performance
11.3.16.3. Service Benchmarking
11.3.16.4. Strategic Initiatives
11.3.17. Cambrex Corporation
11.3.17.1. Participant’s Overview
11.3.17.2. Financial Performance
11.3.17.3. Service Benchmarking
11.3.17.4. Strategic Initiatives
11.3.18. Pfizer Inc.
11.3.18.1. Participant’s Overview
11.3.18.2. Financial Performance
11.3.18.3. Service Benchmarking
11.3.18.4. Strategic Initiatives
11.3.19. Siegfried Holding AG
11.3.19.1. Participant’s Overview
11.3.19.2. Financial Performance
11.3.19.3. Service Benchmarking
11.3.19.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings